| Literature DB >> 26437439 |
Gerhard Fritz1, Christian Henninger2.
Abstract
The Ras-related C3 botulinum toxin substrate 1 (Rac1) belongs to the family of Ras-homologous small GTPases. It is well characterized as a membrane-bound signal transducing molecule that is involved in the regulation of cell motility and adhesion as well as cell cycle progression, mitosis, cell death and gene expression. Rac1 also adjusts cellular responses to genotoxic stress by regulating the activity of stress kinases, including c-Jun-N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38 kinases as well as related transcription factors. Apart from being found on the inner side of the outer cell membrane and in the cytosol, Rac1 has also been detected inside the nucleus. Different lines of evidence indicate that genotoxin-induced DNA damage is able to activate nuclear Rac1. The exact mechanisms involved and the biological consequences, however, are unclear. The data available so far indicate that Rac1 might integrate DNA damage independent and DNA damage dependent cellular stress responses following genotoxin treatment, thereby coordinating mechanisms of the DNA damage response (DDR) that are related to DNA repair, survival and cell death.Entities:
Keywords: DNA damage response; HMG-CoA reductase inhibitors (statins); Rho GTPases; anticancer drugs; chemical carcinogenesis; genotoxic stress; normal tissue damage
Mesh:
Substances:
Year: 2015 PMID: 26437439 PMCID: PMC4693241 DOI: 10.3390/biom5042417
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Pleiotropic inhibitory effects of lovastatin on IR-induced mechanisms of the DDR of endothelial-like cells (EA.hy926). (A) Logarithmically growing EA.hy926 cells were left untreated or were pre-treated overnight with lovastatin (20 μM) before irradiation (IR) (10 Gy) or treatment with the direct oxidant tert-butyl hydroperoxide (t-BOOH) (400 μM). After post-incubation period of 2 h, cells were harvested for Western blot analysis using different phosphospecific antibodies as indicated. PARP and ERK2 expression were analyzed for protein loading control. (B) EA.hy926 cells were pre-treated with different concentration of lovastatin (Lova) before irradiation (IR) with 10 Gy. Two hours later, the phosphorylation level of p–p53 was monitored by Western blot analysis. (C) EA.hy926 cells were pre-treated for 2 h with the Rho-inhibitory ToxB (10 ng/mL) from Clostridium difficile before irradiation was performed (IR, 10 Gy). After further incubation period of 2 h, the level of phosphorylated p53 was determined. For control, cells were also pre-treated with latrunculinB (LatB) (2 μg/mL), which is an inhibitor of actin polymerization. (D) To address the question whether Rac1 is a major target for the observed lovastatin effects, the influence of lovastatin and NSC23766 on IR-induced mechanisms of the DDR was investigated in parallel. EA.hy926 cells were either pre-treated overnight with lovastatin (20 μM) or for 2 h with the Rac1-specific small-molecule inhibitor NSC27633 (30 μM) before irradiation was performed (IR, 10 Gy). After further incubation period of 2 h, the level of phosphorylated p53, Chk2 and H2AX was determined. Since lovastatin and NSC23766 revealed quantitatively similar inhibitory effects, we conclude that Rac1 is a major target that mediates the inhibitory effect of the statin on IR-induced DDR. (E) EA.hy926 cells were pre-treated overnight with lovastatin (20 μM) or for 2 h with the small-molecule Rac1 inhibitor NSC27633 (30 μM) before irradiation was performed (IR, 10 Gy). After further incubation period of either 0.5 h or 2 h, the level of phosphorylated ATM was determined by Western blot analysis. Expression of talin-1 and PARP protein were analyzed as loading control.
Figure 2Model of a putative interference of cytosolic and nuclear Rac1 GTPase with mechanisms of the DDR. Exposure to genotoxins results in a rapid activation of membrane-derived stress responses leading to the activation of stress kinases, including Rac1-dependent activation of SAPK/JNK (1), which can phosphorylate H2AX at position S139 as ATM and ATR kinase do (2). The non-receptor tyrosine kinase c-Abl is able to shuttle between cytoplasm and nucleus and is subject to regulation by both SAPK/JNK and ATM (3). c-Abl is believed to trigger DNA damage dependent apoptotic mechanisms via p73. Both prenylated and non-prenylated Rac1 can translocate into the nucleus by help of karyophyrin (KPNA2) (4). Inside the nucleus, Rac1 can be present in GDP- and GTP-bound state and binds to numerous proteins, including topoisomerase II (Topo II) (4). High levels of free 8-oxoG base increase the level of GTP-bound Rac1 (5). Since the Rac1 effector PAK1 is not only involved in signaling to SAPK/JNK but is present in the nucleus as well (6), it is tempting to speculate that PAK1 mediates DDR-related effects of Rac1. Following DNA damage RhoA GEF (e.g., Net1A) get activated (7) leading to a Fen1 dependent activation of the RhoA/ROCK axis (8), which is important for the organization of the actin cytoskeleton (9). Notably, Rac1 controls subcellular localization of Net1 and PAK1 regulates the activity of Net1. Alterations in nuclear actin structure might provide the structural basis for temporal and spacial accessibility of the chromatin to DDR-related factors (10). In addition, there is evidence that Rac1 is required for the activation of checkpoint kinases (Chk1, 2) and p53 downstream of ATM/ATR (11). Taken together, the data available indicate that Rac1-regulated mechanisms coordinate cellular stress responses to genotoxins that originate either from damaged DNA or emerge from the outer membrane. Targeting of Rac1 signaling is therefore suggested as a promising strategy to pharmacologically interfere with the complex stress responses evoked by DNA damaging anticancer drugs and chemical mutagens. In light of the fact that Rac1 can be inhibited by statins (12) as well as by inhibitors of Rac1-specific GEFs (e.g., NSC23766) and GTP-dependent effector coupling (e.g., EHT1864) (13), Rac1 represents a druggable target as well. Therefore, interfering with Rac1-regulated DDR is suggested to be useful in anticancer therapy, by sensitizing tumor cells and/or protecting normal tissue from the adverse effects of conventional (genotoxic) anticancer drugs and radiotherapy. The numbers in the brackets (from 1 to 13) refer to the preceding text passage in the legend and point to the numbered green dots in the figure.